Last Price
54.13
Today's Change
-1.26 (2.27%)
Day's Change
51.70 - 55.63
Trading Volume
3,666,380
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Brian Lian Ph.D. Dr. Brian Lian Ph.D.
Full Time Employees: 28 28
IPO Date: 2015-04-28 2015-04-28
CIK: 0001607678 0001607678
ISIN: US92686J1060 US92686J1060
CUSIP: 92686J106 92686J106
Beta: 1.00 1.00
Last Dividend: 0.00 0.00
Dcf Diff: 53.55 53.55
Dcf: 0.58 0.58
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
9920 Pacific Heights Boulevard,
San Diego, CA 92121, US
858 704 4660